NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free MLYS Stock Alerts $13.09 +0.29 (+2.27%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$12.73▼$13.2350-Day Range$10.75▼$16.1552-Week Range$5.85▼$17.70Volume113,802 shsAverage Volume123,668 shsMarket Capitalization$649.66 millionP/E RatioN/ADividend YieldN/APrice Target$33.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside155.9% Upside$33.50 Price TargetShort InterestBearish3.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.44) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector544th out of 908 stocksPharmaceutical Preparations Industry243rd out of 420 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.77% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 2.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.44) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesMay 3, 2024 | msn.comMineralys Therapeutics to Unveil First Quarter Financial ResultsMay 2, 2024 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024May 3, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.April 2, 2024 | msn.comGoldman starts Mineralys at buy, cites upcoming drug dataMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsMarch 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...May 3, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesFebruary 9, 2024 | seekingalpha.comMineralys: 2nd Half 2024 Hypertension Data ReadoutFebruary 9, 2024 | bizjournals.comMineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressureFebruary 9, 2024 | msn.comMineralys Therapeutics Equity Sales: Investor Impact ReportFebruary 9, 2024 | msn.comMineralys Therapeutics Announces Strategic Purchase AgreementFebruary 8, 2024 | msn.comMineralys Therapeutics stock jumps on $120M private placement financingFebruary 8, 2024 | finance.yahoo.comMineralys Therapeutics Announces $120 Million Private Placement FinancingJanuary 29, 2024 | finance.yahoo.comMineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology ConferenceSee More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/03/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$33.50 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+155.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.48% Return on Assets-25.52% Debt Debt-to-Equity RatioN/A Current Ratio23.76 Quick Ratio23.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book2.23Miscellaneous Outstanding Shares49,630,000Free Float33,134,000Market Cap$649.66 million OptionableOptionable Beta2.05 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Comp: $69.33kMr. Jon Congleton (Age 61)CEO & Director Comp: $775.77kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $655.58kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsZymeworksNYSE:ZYMEWave Life SciencesNASDAQ:WVEORIC PharmaceuticalsNASDAQ:ORICCogent BiosciencesNASDAQ:COGTSIGA TechnologiesNASDAQ:SIGAView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 3,181 shares on 4/29/2024Ownership: 0.016%PNC Financial Services Group Inc.Bought 4,099 shares on 3/22/2024Ownership: 0.010%Catalys Pacific LLCBought 9,194,579 shares on 2/14/2024Ownership: 22.371%Sectoral Asset Management Inc.Sold 235,153 shares on 2/14/2024Ownership: 1.473%Pale Fire Capital SEBought 34,743 shares on 2/14/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued twelve-month price targets for Mineralys Therapeutics' stock. Their MLYS share price targets range from $30.00 to $37.00. On average, they predict the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 155.9% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2024? Mineralys Therapeutics' stock was trading at $8.60 at the beginning of 2024. Since then, MLYS stock has increased by 52.2% and is now trading at $13.09. View the best growth stocks for 2024 here. When is Mineralys Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MLYS earnings forecast. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.61) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.24. What ETFs hold Mineralys Therapeutics' stock? ETFs with the largest weight of Mineralys Therapeutics (NASDAQ:MLYS) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) and When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, LP and Samsara Biocapital Gp, Llc. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.